Please login to the form below

Not currently logged in
Email:
Password:

Accelerated approval not working

The US FDA's accelerated approval programme for NMEs is not achieving its aim, according to a multi-centre study

The US Food and Drug Administration's (FDA's) accelerated approval programme for new molecular entities (NMEs) is not achieving its aim, according to a multi-centre study published in the Journal of Clinical Oncology.

The initiative was set up in 1992 to try to speed up access to therapies for life-threatening conditions, including cancer. Researchers looked at data for accelerated and regular FDA approvals in oncology since 1995. The study shows that oncology NMEs in the accelerated programme reached market in a median time of 7.3 years and new drugs going through regular approval took a median of 7.2 years.

One of the problems, particularly for small biotech companies, is the cost of the large-scale studies now required by the regulators. The authors call for the FDA to return to basing approval for potentially life-saving drugs on smaller studies, in order to expedite access to new treatments for patients with terminal conditions.

28th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics